Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects
暂无分享,去创建一个
Nicola Clementi | E. Criscuolo | M. Castelli | M. Clementi | N. Mancini | R. Burioni | V. Amato | A. Ambrosi | R. Diotti
[1] D. Lilleri,et al. Human cytomegalovirus (HCMV)‐specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid‐organ transplant recipients , 2018, Journal of medical virology.
[2] D. Cook,et al. Kinetics of Serological Responses in Critically Ill Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009–2011 , 2018, The Journal of infectious diseases.
[3] Nicola Clementi,et al. Synergy evaluation of anti‐Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle , 2018, Antiviral research.
[4] C. S. Nelson,et al. Maternal immune correlates of protection against placental transmission of cytomegalovirus. , 2017, Placenta.
[5] A. Tarr,et al. Entry inhibition of HSV‐1 and ‐2 protects mice from viral lethal challenge , 2017, Antiviral research.
[6] Nicola Clementi,et al. Role and potential therapeutic use of antibodies against herpetic infections. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] S. Bailly,et al. Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[8] Nicola Clementi,et al. Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes. , 2016, Drug discovery today.
[9] Karen G. Dowell,et al. Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control , 2016, PLoS pathogens.
[10] R. Eisenberg,et al. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific , 2015, Journal of Virology.
[11] W. Jacobs,et al. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease , 2015, eLife.
[12] Nicola Clementi,et al. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein , 2015, Gut.
[13] T. Mertens,et al. Natural Killer Cells Can Inhibit the Transmission of Human Cytomegalovirus in Cell Culture by Using Mechanisms from Innate and Adaptive Immune Responses , 2014, Journal of Virology.
[14] R. Eisenberg,et al. Dissection of the Antibody Response against Herpes Simplex Virus Glycoproteins in Naturally Infected Humans , 2014, Journal of Virology.
[15] H. Friedman,et al. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. , 2014, The Journal of infectious diseases.
[16] R. Eisenberg,et al. Repertoire of Epitopes Recognized by Serum IgG from Humans Vaccinated with Herpes Simplex Virus 2 Glycoprotein D , 2014, Journal of Virology.
[17] A. Steven,et al. Mechanism of Neutralization of Herpes Simplex Virus by Antibodies Directed at the Fusion Domain of Glycoprotein B , 2013, Journal of Virology.
[18] Guixiu Shi,et al. Systemic Autoimmune Diseases , 2013, Clinical and Developmental Immunology.
[19] M. Franti,et al. Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. , 2013, Virology.
[20] J. Schiffer. Mucosal HSV-2 Specific CD8+ T-Cells Represent Containment of Prior Viral Shedding Rather than a Correlate of Future Protection , 2013, Front. Immunol..
[21] M. dal Peraro,et al. Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides , 2013, Clinical & developmental immunology.
[22] D. Jäger,et al. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody , 2013, Proceedings of the National Academy of Sciences.
[23] D. Shah,et al. Antibody biodistribution coefficients , 2013, mAbs.
[24] Nicola Clementi,et al. Neutralization Interfering Antibodies: A “Novel” Example of Humoral Immune Dysfunction Facilitating Viral Escape? , 2012, Viruses.
[25] D. Bernstein,et al. Efficacy results of a trial of a herpes simplex vaccine. , 2012, The New England journal of medicine.
[26] R. Eisenberg,et al. Antibody-Induced Conformational Changes in Herpes Simplex Virus Glycoprotein gD Reveal New Targets for Virus Neutralization , 2011, Journal of Virology.
[27] R. Eisenberg,et al. Capturing the Herpes Simplex Virus Core Fusion Complex (gB-gH/gL) in an Acidic Environment , 2011, Journal of Virology.
[28] D. Jäger,et al. Impact of Valency of a Glycoprotein B-Specific Monoclonal Antibody on Neutralization of Herpes Simplex Virus , 2010, Journal of Virology.
[29] P. Kalinski,et al. Reevaluating the CD8 T-Cell Response to Herpes Simplex Virus Type 1: Involvement of CD8 T Cells Reactive to Subdominant Epitopes , 2008, Journal of Virology.
[30] F. Gudé,et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities , 2007, Clinical and experimental immunology.
[31] A. Tarr,et al. Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein , 2007, Journal of Virology.
[32] R. Eisenberg,et al. Antigenic and Mutational Analyses of Herpes Simplex Virus Glycoprotein B Reveal Four Functional Regions , 2007, Journal of Virology.
[33] F. Aoki,et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. , 2002, The New England journal of medicine.
[34] M. Muggeridge. Characterization of cell-cell fusion mediated by herpes simplex virus 2 glycoproteins gB, gD, gH and gL in transfected cells. , 2000, The Journal of general virology.
[35] A. Adimora,et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. , 1999, JAMA.
[36] R. Rozenshteyn,et al. Characterization of a Type-Common Human Recombinant Monoclonal Antibody to Herpes Simplex Virus with High Therapeutic Potential , 1998, Journal of Clinical Microbiology.
[37] R. Eisenberg,et al. Monoclonal Antibodies to Distinct Sites on Herpes Simplex Virus (HSV) Glycoprotein D Block HSV Binding to HVEM , 1998, Journal of Virology.
[38] J. Lubinski,et al. The gH-gL Complex of Herpes Simplex Virus (HSV) Stimulates Neutralizing Antibody and Protects Mice against HSV Type 1 Challenge , 1998, Journal of Virology.
[39] G. Mertz,et al. Locations of herpes simplex virus type 2 glycoprotein B epitopes recognized by human serum immunoglobulin G antibodies , 1996, Journal of virology.
[40] P. Fine,et al. Correlates of vaccine-induced protection: methods and implications , 2013 .